Skip to main content
. 2021 Mar 5;12:609421. doi: 10.3389/fimmu.2021.609421

Figure 4.

Figure 4

Clinical efficacy after BCMA-7 × 19 CAR-T infusion. (A) Duration of response and survival after BCMA-7X19 CAR-T cell infusion. (B) Scheme for CAR-T preparation and treatment. (C) Patient 1, serum immunoglobulin IgG, IgA, IgM are in the normal range, both before and after infusion. (D) Patient 1, representative CT scans at different baselines (baseline1: First extramedullary recurrence of multiple myeloma; 1 year after Len and DXM induction therapy shown in baseline 2: progression of extramedullary recurrence; baseline 3: 1 month before BCMA-7X19 CAR-T infusion); and CT scans post-CAR-T cell infusion 1, 4, and 10 months. Scale bars, 1 cm. (E) Patient 2, monitoring of urine light chain protein and (F) Serum immunoglobulin IgG, Ig A, Ig M levels before and after treatment. (G) Serum kinetics of a panel of cytokines in patients who received infusions with high doses of CAR-T cells, as determined by Luminex multiplex assay (R&D Systems) Horizontal lines denote mean values.